Actively Recruiting
Dose-Escalation and Expansion Study to Evaluate Budoprutug TNT119 Safety and Effects in Adults With Systemic Lupus Erythematosus
Led by Climb Bio, Inc. · Updated on 2026-10-20
30
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating budoprutug, a humanized monoclonal antibody targeting CD19, in adults aged 18 to 65 years with active, seropositive systemic lupus erythematosus SLE who have not adequately responded to standard treatments. This Phase 1b2a, open-label study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early signs of efficacy of budoprutug in this patient group. Budoprutug is given as two intravenous infusions, administered 14 days apart, in escalating dose groups. The study includes multiple cohorts receiving different dose levels followed by a dose expansion cohort, all receiving single IV doses on Day 1 and Day 15. The study monitors how budoprutug affects B cells and immunoglobulin levels over time, among other treatment effects. Participants will be closely assessed up to 28 weeks after treatment, with evaluations including adverse events, laboratory tests, vital signs, electrocardiograms, and changes in disease activity scores such as SLEDAI-2K and urine protein creatinine ratio. Researchers will also monitor drug levels, immune responses, and changes in B-cell counts. The total participation duration extends through these assessments to gather comprehensive safety and pharmacodynamic data.
CONDITIONS
Brief Title
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
Research Team
C
Climb Bio Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here